GLP-1 Receptor Agonists Show Promise in Treating Idiopathic Intracranial Hypertension

Recent findings indicate that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may enhance clinical outcomes for individuals diagnosed with idiopathic intracranial hypertension (IIH). A study published in JAMA Neurology has revealed that GLP-1 RA treatment yields better results compared to traditional therapies commonly used for managing IIH.

The research, carried out by a team from the Virginia Commonwealth University Health System, evaluated data from the TriNetX U.S. Collaborative Network, spanning from 2005 to 2024. The study involved analyzing electronic health records from 67 healthcare institutions to assess the effects of GLP-1 RA therapy initiated within six months of an IIH diagnosis. A control group was established, consisting of patients treated with standard medications like acetazolamide, topiramate, and dietary counseling.

In total, the study identified 44,373 patients with IIH, with 555 receiving GLP-1 RA therapy and another 555 serving as non-users, matched through propensity score analysis. The results demonstrated that those treated with GLP-1 RAs experienced significantly lower medication use and a reduction in symptoms such as headaches, visual disturbances, and papilledema, with risk ratios indicating improvements (0.53, 0.45, 0.60, and 0.19, respectively). Additionally, the GLP-1 RA group exhibited a decreased likelihood of requiring surgical procedures and a lower mortality risk (risk ratios of 0.44 and 0.36, respectively). Notably, no significant differences in mean body mass index (BMI) were observed at follow-up between the two groups.

Further analysis indicated that while greater weight loss was associated with bariatric surgery, GLP-1 RA therapy resulted in more favorable clinical outcomes.

The authors of the study suggest that these findings indicate a potential benefit of GLP-1 RAs in the management of IIH, but they emphasize the need for prospective studies to confirm these results.

For more detailed information, the complete study can be accessed in JAMA Neurology.